VeriSilicon Launches ISP9000: The Next-Generation AI-Embedded ISP for Intelligent Vision Applications
2.4.2025 02:00:00 CEST | Business Wire | Press Release
VeriSilicon (688521.SH) today unveiled its ISP9000 series Image Signal Processing (ISP) IP, a next-generation AI-embedded ISP solution designed to address the evolving demands of intelligent vision applications. Built on a flexible AI-optimized architecture, ISP9000 delivers exceptional image quality, low-latency multi-sensor management, and seamless AI integration, making it ideal for advanced use cases, such as intelligent machines, surveillance cameras, and AI PCs.
With its AI-powered ISP capabilities, VeriSilicon’s ISP9000 series IP delivers superior image quality. It integrates advanced AI noise reduction (AI NR) algorithms, combining multi-scale 2D and 3D noise reduction with YUV-domain chroma noise reduction (CNR) in a multi-domain noise reduction architecture. This effectively minimizes noise while preserving fine details, particularly in extremely low-light conditions. Its support for triple-exposure High Dynamic Range (HDR) processing and dynamic range compression, with a 20-bit pipeline, ensures that high dynamic range scenes retain critical details in both bright and dark areas. Beyond that, the ISP9000’s 3A capabilities, including auto exposure (AE), auto focus (AF), and auto white balance (AWB), support up to 25 configurable regions of interest (ROI), which enables AI-assisted object detection and recognition. Additionally, users can integrate third-party 3A libraries, providing the flexibility to tailor 3A algorithms for specific application needs.
The ISP9000 supports multi-sensor configurations and leverages hardware-accelerated multi-context management (MCM) and frame slicing mechanisms to enable efficient data stream switching. This ensures the stability of multi-sensor data streams while providing low latency and cost efficiency. Supporting up to 16 sensors, the ISP9000 integrates VeriSilicon’s VI200 video interface IP for seamless connectivity with mainstream MIPI Rx interfaces. Its scalable multi-core architecture supports high-performance processing with up to 8K@30fps and 4K@120fps. Through VeriSilicon’s FLEXA SBI interface, the ISP9000 enables optimized data transmission to video encoders, Neural Network Processing Units (NPUs), or display processors, enabling optimized subsystem solutions.
Furthermore, the ISP9000 is equipped with VeriSilicon’s AcuityPercept, an AI-powered automatic ISP tuning system, to enhance its intelligent vision capabilities. Unlike traditional tuning focused on human-perceived image quality, AcuityPercept optimizes the ISP settings for superior object recognition in the AI/NPU pipeline, adapting to specific AI algorithms and application requirements.
“As AI becomes increasingly embedded in devices across a wide range of applications, and with the rapid advancement of robotics, the demand for next-generation ISPs to meet evolving product requirements continues to grow,” said Weijin Dai, Chief Strategy Officer, Executive Vice President, and General Manager of the IP Division at VeriSilicon. “In addition to delivering high image quality and low power consumption, next-generation ISPs must efficiently support multiple sensors with fast context switching and low latency, and optimize output for both NPUs and human vision. They should also enable automatic tuning in conjunction with target perception NPUs. The ISP9000 is architected with these requirements in mind and has been developed through close collaboration with leading customers. By embedding AI technology, ISP9000 achieves exceptional image quality in extremely low-light conditions, surpassing the capabilities of traditional computer vision technologies.”
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401360621/en/
Contacts
Media Contact: press@verisilicon.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom